Table 2 Frequency of T cell subsets in the healthy controls and kidney transplant patients pre- and post-transplantation
pre-Tx (N = 36) | post-Tx (N = 36) | HC (N = 27) | p value | |||
|---|---|---|---|---|---|---|
pre-Tx vs post-Tx | HC vs pre-Tx | HC vs post-Tx | ||||
CD3+/Lymphocytes (%) | 65.7 (59.5–74.6) | 74.7 (67.3–81.5) | 69.7 (67.0–74.0) | 0.001 | ns | 0.022 |
CD4+/CD3+ (%) | 58.9 (48.6–72.9) | 52.0 (41.0–67.7) | 62.1 (49.3–71.5) | 0.007 | ns | 0.042 |
Naïve CD4+/CD4+ (%) | 34.0 (18.8–47.8) | 22.3 (13.2–36.6) | 36.8 (27.8–47.8) | 0.002 | ns | 0.005 |
CM CD4+/CD4+ (%) | 28.0 (21.5–33.8) | 25.3 (19.8–32.8) | 28.7 (22.9–34.3) | ns | ns | ns |
EM CD4+/CD4+ (%) | 33.9 (19.3–43.0) | 39.6 (26.7–51.0) | 28.9 (21.3–36.9) | 0.002 | ns | 0.004 |
TEMRA CD4+/CD4+ (%) | 4.1 (3.0–6.3) | 4.2 (3.3–7.4) | 4.3 (3.1–5.9) | ns | ns | ns |
Tfh CD4+/CD4 + CXCR5+ (%) | 6.2 (4.0–8.9) | 6.0 (3.8–10.0) | 5.8 (4.0–13.0) | ns | ns | ns |
Treg CD4+/CD4+ (%) | 5.1 (3.8–6.6) | 3.8(2.9–5.6) | 5.7 (4.7–6.5) | 0.005 | ns | 0.003 |
CD4 + CD28−/CD4+ (%) | 2.6 (1.1–7.3) | 3.6 (1.3–9.3) | 1.5 (0.6–3.1) | ns | ns | 0.027 |
Naïve CD4+/CM CD4+ ratio | 1.1 (0.6–1.8) | 0.8 (0.6–1.7) | 1.3 (0.8–1.9) | 0.036 | ns | ns |
Naïve CD4+/EM CD4+ ratio | 1.0 (0.5–2.4) | 0.6 (0.3–1.3) | 1.1 (0.8–2.1) | < 0.001 | ns | 0.003 |
CD8+/CD3+ (%) | 25.8 (17.4–34.6) | 31.4 (21.7–45.1) | 26.1 (21.3–32.2) | 0.003 | ns | ns |
Naïve CD8+/CD8+ (%) | 23.0 (16.7–53.1) | 19.3 (8.6–37.9) | 31.7 (18.4–53.8) | < 0.001 | ns | 0.019 |
CM CD8+/CD8+ (%) | 3.4 (2.4–6.5) | 2.3 (1.5–4.0) | 3.4 (2.6–5.2) | < 0.001 | ns | 0.010 |
EM CD8+/CD8+ (%) | 34.1 (24.0–43.8) | 33.6 (22.0–47.3) | 31.2 (25.3–49.8) | ns | ns | ns |
TEMRA CD8+/CD8+ (%) | 24.6 (17.5–34.7) | 36.5 (28.2–48.9) | 19.7 (13.9–34.3) | < 0.001 | ns | 0.002 |
CD8 + CD28−/CD8+ (%) | 39.3 (19.3–52.8) | 43.0 (21.8–65.6) | 26.8 (16.7–42.8) | ns | ns | 0.010 |
CD4+/CD8+ ratio | 2.3 (1.5–3.9) | 1.6 (0.9–2.8) | 2.3 (1.3–3.3) | 0.002 | ns | 0.049 |